United States Diabetes Care Devices Market Outlook to 2025 - Glucose Monitoring and Insulin Delivery

Table of Contents

• 1.1 List of Tables 5
• 1.2 List of Figures 7

2 Introduction 8

• 2.1 What Is This Report About? 8
• 2.2 Diabetes Care Devices Market Segmentation 8
• 2.3 Definitions of Markets Covered in the Report 9

3 Diabetes Care Devices Market, United States 11

• 3.1 Diabetes Care Devices Market, United States, Revenue ($m), 2015-2025 11
• 3.2 Diabetes Care Devices Market, United States, Revenue Mix ($m), 2019 13
• 3.3 Diabetes Care Devices Market, United States, Category Contribution by Revenue ($m), 2019 14
• 3.4 Diabetes Care Devices Market, United States, Revenue ($m), 2015-2025 15
• 3.5 Diabetes Care Devices Market, United States, Volume (Units), 2015-2025 17
• 3.6 Diabetes Care Devices Market, United States, Volume (Units), 2015-2025 19
• 3.7 Diabetes Care Devices Market, United States, Company Share by Revenue ($m), 2019 21

4 Glucose Monitoring Market, United States 23

• 4.1 Glucose Monitoring Market, United States, Revenue ($m), 2015-2025 23
  • 4.1.1 Blood Glucose Meters Market, United States, Revenue ($m), by Segment, 2015-2025 25
• 4.2 Glucose Monitoring Market, United States, Volume (Units), 2015-2025 27
  • 4.2.1 Blood Glucose Meters Market, United States, Volume (Units), by Segment, 2015-2025 29
• 4.3 Glucose Monitoring Market, United States, Average Price ($) , 2015-2025 31
• 4.4 Glucose Monitoring Market, United States, Distribution Share by Revenue ($m), 2019 32
• 4.5 Glucose Monitoring Market, United States, Company Share by Revenue ($m), 2019 33

5 Insulin Delivery Market, United States 34

• 5.1 Insulin Delivery Market, United States, Revenue Mix ($m), 2019 34
• 5.2 Insulin Delivery Market, United States, Segment Contribution (%), 2019 35
• 5.3 Insulin Delivery Market, United States, Revenue ($m), 2015-2025 36
  • 5.3.1 Insulin Pens Market, United States, Revenue ($m), by Segment, 2015-2025 38
  • 5.3.2 Insulin Pumps Market, United States, Revenue ($m), by Segment, 2015-2025 40
• 5.4 Insulin Delivery Market, United States, Volume (Units), 2015-2025 42
  • 5.4.1 Insulin Pens Market, United States, Volume (Units), by Segment, 2015-2025 44
  • 5.4.2 Insulin Pumps Market, United States, Volume (Units), by Segment, 2015-2025 46
• 5.5 Insulin Delivery Market, United States, Average Price ($), 2015-2025 48
• 5.6 Insulin Delivery Market, United States, Distribution Share by Revenue ($m), 2019 49
• 5.7 Insulin Delivery Market, United States, Company Share by Revenue ($m), 2019 50

6 Overview of Key Companies in United States, Diabetes Care Devices Market 52

• 6.1 DexCom Inc 52
  • 6.1.1 Company Overview 52
• 6.2 Medtronic Plc 52
  • 6.2.1 Company Overview 52
• 6.3 Novo Nordisk AS 52
  • 6.3.1 Company Overview 52
• 6.4 Eli Lilly and Co 53
  • 6.4.1 Company Overview 53
• 6.5 Abbott Laboratories 53
  • 6.5.1 Company Overview 53
• 6.6 Sanofi 53
  • 6.6.1 Company Overview 53
• 6.7 Insulet Corp 54
  • 6.7.1 Company Overview 54

7 Diabetes Care Devices Market Pipeline Products 55

8 Financial Deals Landscape 56

• 8.1 Acquisition 56
  • 8.1.1 CCS Medical Holdings May Sell Itself 56
  • 8.1.2 KNOW Bio Acquires Clinical Sensors 58
  • 8.1.3 Medtronic Acquires Klue 59
  • 8.1.4 Cerecor Acquires Aevi Genomic Medicine 60
  • 8.1.5 Dare Bioscience Acquires Microchips Biotech 62
  • 8.1.6 Best Buy Acquires Critical Signal Technologies 64
• 8.2 Debt Offerings 65
  • 8.2.1 Thermo Fisher Scientific Prices Public Offering of 2.375% Notes Due 2032 for USD668 Million 65
  • 8.2.2 Thermo Fisher Scientific Prices Public Offering of 1.750% Notes Due 2027 for USD668 Million 67
  • 8.2.3 Pfizer Raises USD1.25 Billion in Public Offering of 2.625% Notes Due 2030 69
  • 8.2.4 Thermo Fisher Scientific Prices Public Offering of 4.133% Notes Due 2025 for USD1.1 Billion 71
  • 8.2.5 Thermo Fisher Scientific Prices Public Offering of 4.497% Notes Due 2030 for USD1.1 Billion 73
  • 8.2.6 Guided Therapeutics Raises USD0.7 Million in Public Offering of Convertible Note 75
  • 8.2.7 Eli Lilly Prices Public Offering of 0.625% Notes Due 2031 for USD665.5 Million 76
  • 8.2.8 Eli Lilly Prices Public Offering of 1.7% Notes Due 2049 for USD1.1 Billion 78
  • 8.2.9 Thermo Fisher Scientific Raises USD990 Million in Public Offering of 1.500% Notes Due 2039 80
  • 8.2.10 Thermo Fisher Scientific Raises USD900 Million in Public Offering of 2.600% Notes Due 2029 83
  • 8.2.11 Thermo Fisher Scientific Raises USD1.1 Billion in Public Offering of 1.875% Notes Due 2049 85
  • 8.2.12 Thermo Fisher Scientific Raises USD880 Million in Public Offering of 0.500% Notes Due 2028 88
  • 8.2.13 Thermo Fisher Scientific Raises USD990 Million in Public Offering of 0.875% Notes Due 2031 91
  • 8.2.14 Thermo Fisher Scientific Raises USD880 Million in Public Offering of 0.125% Notes Due 2025 94
  • 8.2.15 Insulet Raises USD800 Million in 0.375% Convertible Senior Notes Due 2026 97
  • 8.2.16 Senseonics Holdings Raises USD82 Million in Private Placement of 5.25% Notes Due 2025 99
  • 8.2.17 Becton Dickinson Raises USD669.7 Million in Public Offering of 0.174% Notes Due 2021 100
  • 8.2.18 Becton Dickinson Raises USD669.7 Million in Public Offering of 1.208% Notes Due 2026 102
  • 8.2.19 Becton Dickinson Raises USD893 Million in Public Offering of 0.632% Notes due 2023 104
• 8.3 Equity Offerings 106
  • 8.3.1 Tenax Therapeutics Prices Private Placement of Shares and Warrants for USD2.8 Million 106
  • 8.3.2 Xeris Pharma Raises USD42.7 Million in Public Offering of Shares 107
  • 8.3.3 Albireo Pharma Raises USD46 Million in Public Offering of Shares 109
  • 8.3.4 Guided Therapeutics Raises USD0.7 Million in Private Placement of Units 111
  • 8.3.5 PhysioLogic Devices Raises Funds through Financing 112
  • 8.3.6 Senseonics Plans to Raise up to USD50 Million in Public Offering of Shares 113
  • 8.3.7 Organogenesis Prices USD45 Million Public Offering of Shares 114
  • 8.3.8 Organogenesis Plans to Raise up to USD100 Million in Public Offering of Securities 116
  • 8.3.9 Xeris Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 117
  • 8.3.10 Valeritas Holdings Plans to Raise up to USD10.7 Million in Public Offering of Shares 118
  • 8.3.11 Senseonics Holdings Raises USD25 Million in Public Offering of Shares 119
  • 8.3.12 Glucose Biosensor Systems Files Registration Statement for IPO of Shares 121
  • 8.3.13 MannKind to Raise up to USD50 Million in Public Offering of Shares 122
  • 8.3.14 Dance Biopharm Raises USD20.5 Million in Private Placement 124
• 8.4 Partnerships 125
  • 8.4.1 Abbott Labs and Insulet Enter into Partnership 125
  • 8.4.2 Biocorp Production Enters into Agreement with Amalgam Rx (iSage Rx) 126
  • 8.4.3 Senseonics Enters into Partnership with Companion Medical 127
  • 8.4.4 Abbott Labs Enters into Agreement with Bigfoot Biomedical 128
  • 8.4.5 Trividia Health and Mellitus Health Form Partnership 129
  • 8.4.6 Solys Diagnostics Enters into Licensing Agreement with Liquid Sensing 130
  • 8.4.7 Sanofi and Abbott Enter into Partnership 131
  • 8.4.8 Medtronic and Tidepool to Enter into Partnership 132
  • 8.4.9 LifeScan Enters into Distribution Agreement with Sanvita Medical 133
• 8.5 Private Equity 134
  • 8.5.1 Becton Dickinson Shareholders Reject Mini Tender Offer from TRC Capital 134
  • 8.5.2 Blackstone Group and Cinven May Bid for Smiths Medical 135
  • 8.5.3 AgaMatrix and WaveForm Technologies Raises USD56 Million in Financing 137
• 8.6 Venture Financing 139
  • 8.6.1 Modular Medical to Raise Funds through Venture Financing 139
  • 8.6.2 Fractyl Labs Raises USD44.8 Million in Venture Financing 140
  • 8.6.3 Bigfoot Biomedical Raises USD45 Million in Initial Tranche of Series C Financing 141
  • 8.6.4 VivaChek Labs Raises USD14.2 Million in Series C Financing 143
  • 8.6.5 Hygieia Raises USD1.3 Million in Venture Financing 144
  • 8.6.6 Eccrine Systems Raises USD1.9 Million in Venture Financing 145
  • 8.6.7 Accessible Diagnostics Raises USD0.2 Million in Venture Financing 146
  • 8.6.8 Amalgam Rx (iSage Rx) Secures USD0.65 Million in Venture Financing 147
  • 8.6.9 MuscleSound Raises USD0.8 Million in Venture Financing 148
  • 8.6.10 Informed Data Systems (One Drop) Raises USD40 Million in Series B Financing 149
  • 8.6.11 TecMed Raises Funds through Venture Financing 150
  • 8.6.12 Thermalin Raises Additional USD12.2 Million in Venture Financing 151
  • 8.6.13 VivaChek Laboratories Raises Funds through Venture Financing 152
  • 8.6.14 POPS! Diabetes Care Secures USD6 Million in Series A Funding 153
  • 8.6.15 Beta Bionics Raises USD63 Million in Series B2 Financing 154
  • 8.6.16 Encellin Raises USD1.6 Million in Venture Financing 156
  • 8.6.17 Eccrine Systems Raises USD0.6 Million in Venture Financing 157
  • 8.6.18 PhysioLogic Devices to Raise USD3 Million in Venture Financing 158
  • 8.6.19 Intuity Medical (Rosedale Medical) Raises USD26.27 Million in Venture Financing 159
  • 8.6.20 Mighty Well Raises Funds through Venture Financing 160

9 Appendix 161

• 9.1 Research Methodology 162
  • 9.1.1 Coverage 162
  • 9.1.2 Secondary Research 162
  • 9.1.3 Primary Research 163
  • 9.1.4 Market Modeling and Forecasting 163
  • 9.1.5 Company Share Analysis 165
  • 9.1.6 Distribution Share Analysis 165
  • 9.1.7 Benchmarking 166
• 9.2 GlobalData Consulting 166
• 9.3 Contact Us 167